Neurodevelopmental issues (NDDs) are a heterogeneous and extremely prevalent group of psychiatric situations marked by impairments in the nervous system. Their onset happens throughout gestation, and the alterations are noticed all through the postnatal life. Although many genetic and environmental danger elements have been described in this context, the interactions between them problem the understanding of the pathways related to NDDs.
Transcription elements (TFs) – a bunch of over 1,600 proteins that may work together with DNA, regulating gene expression by modulation of RNA synthesis, signify some extent of convergence for completely different danger elements. In addition, TFs manage vital processes like angiogenesis, blood-brain barrier formation, myelination, neuronal migration, immune activation, and many others in a time and location-dependent means.
In this assessment, we summarize essential TF alterations in NDD and related issues, together with particular impairments noticed in animal fashions, and, lastly, set up hypotheses to elucidate how these proteins could also be vital mediators in the context of genome-environment interactions.
Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial operate and calcium signaling
The mobile and molecular mechanisms that drive neurodegeneration stay poorly outlined. Recent scientific trial failures, tough prognosis, unsure etiology, and lack of healing therapies prompted us to re-examine different hypotheses of neurodegenerative pathogenesis. Recent studies set up that mitochondrial and calcium dysregulation happen early in many neurodegenerative ailments (NDDs), together with Alzheimer’s illness, Parkinson’s illness, Huntington’s illness, and others.
However, causal molecular proof of mitochondrial and metabolic contributions to pathogenesis stays inadequate. Here we summarize the information supporting the speculation that mitochondrial and metabolic dysfunction outcome from numerous etiologies of neuropathology.
We present a present and complete assessment of the literature and interpret that faulty mitochondrial metabolism is upstream and major to protein aggregation and different dogmatic hypotheses of NDDs. Finally, we determine gaps in data and suggest therapeutic modulation of mCa2+ change and mitochondrial operate to alleviate metabolic impairments and deal with NDDs.
Protein phosphatase 2A – construction, operate and position in neurodevelopmental issues
Neurodevelopmental issues (NDDs), together with mental incapacity (ID), autism and schizophrenia, have excessive socioeconomic affect, but poorly understood etiologies. A current surge of large-scale genome or exome sequencing research has recognized a mess of largely de novo mutations in subunits of the protein phosphatase 2A (PP2A) holoenzyme which are strongly related to NDDs.

PP2A is accountable for at the least 50% of complete Ser/Thr dephosphorylation in most cell varieties and is predominantly discovered as trimeric holoenzymes composed of catalytic (C), scaffolding (A) and variable regulatory (B) subunits. PP2A can exist in practically 100 completely different subunit combos in mammalian cells, dictating distinct localizations, substrates and regulatory mechanisms.
PP2A is properly established as a regulator of cell division, progress, and differentiation, and the roles of PP2A in most cancers and numerous neurodegenerative issues, similar to Alzheimer’s illness, have been reviewed in element. This Review summarizes and discusses current studies on NDDs related to mutations of PP2A subunits and PP2A-associated proteins. We additionally focus on the potential affect of those mutations on the construction and operate of the PP2A holoenzymes and the etiology of NDDs.
Muscarinic Acetylcholine Receptor M1 mutations inflicting neurodevelopmental dysfunction and epilepsy
De novo uncommon damaging variants in genes concerned in vital developmental pathways, notably regulation of synaptic transmission, have emerged as a frequent explanation for neurodevelopmental issues (NDD). NDD present nice locus heterogeneity and for most of the related genes there’s substantial phenotypic variety, together with epilepsy, mental incapacity, autism spectrum dysfunction, motion issues and combos thereof.
We report two unrelated sufferers, a younger lady with early-onset refractory epilepsy, extreme incapacity and progressive cerebral and cerebellar atrophy and a second lady with delicate dysmorphism, world developmental delay and average mental incapacity in whom trio-based complete exome sequencing evaluation uncovered de novo missense variants in CHRM1.
Biochemical analyses of one of many NDD-associated variants proved that it brought on a discount in protein ranges and an impaired mobile trafficking. In addition, the mutated receptor confirmed faulty activation of intracellular signalling pathways. Our information strengthen the idea that mind diminished muscarinic signalling lowers seizure threshold and severely impairs neurodevelopment. This article is protected by copyright. All rights reserved.
Marine Polysaccharides as a Versatile Biomass for the Construction of Nano Drug Delivery Systems
Marine biomass is a treasure trove of supplies. Marine polysaccharides have the traits of biocompatibility, biodegradability, non-toxicity, low price, and abundance. An huge number of polysaccharides might be extracted from marine organisms similar to algae, crustaceans, and microorganisms. The most studied marine polysaccharides embody chitin, chitosan, alginates, hyaluronic acid, fucoidan, carrageenan, agarose, and Ulva. Marine polysaccharides have a variety of purposes in the sphere of biomedical supplies, similar to drug supply, tissue engineering, wound dressings, and sensors.
The drug supply system (DDS) can comprehensively management the distribution of medicine in the organism in area, time, and dosage, thereby growing the utilization effectivity of medicine, lowering prices, and lowering poisonous unwanted side effects. The nano-drug supply system (NDDS), on account of its small measurement, can operate on the subcellular degree in vivo.
Rabbit anti Human TNFRSF10D Monoclonal Antibody |
|||
MBS2543981-02mL | MyBiosource | 0.2mL | 550 EUR |
Human TNFRSF10D siRNA |
|||
20-abx937586 | Abbexa |
|
|
Anti-Human TNFRSF10D Antibody |
|||
101-M654 | ReliaTech | 100 µg | 399 EUR |
Description: TNF-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand and TNFSF10, is a type II transmembrane protein with a carboxy-terminal extracellular domain that exhibits homology to other TNF superfamily members. TRAIL binds at least five different receptors: TRAIL R1 (DR4), R2 (DR5), R3 (DcR1), R4 (DcR2), and osteoprotegerin (OPG). TRAIL receptors all exhibit cysteine-rich repeats characteristic of the TNF receptor superfamily. TRAIL R1 and R2 are type 1 transmembrane proteins with intracellular death domains (DD) and, subsequently, have the ability to mediate TRAIL-induced apoptosis. The remaining receptors are decoys that may regulate TRAIL activity by competing for binding sites with TRAIL R1 and R2. TRAIL R3 is membrane-associated via GPI linkage. TRAIL R4 is a type 1 transmembrane receptor, but exhibits a truncated cytoplasmic domain. Like the active receptors TRAIL R1 and R2, OPG has a DD motif but is a soluble protein. |
|||
TNFRSF10D siRNA (Human) |
|||
MBS8232418-15nmol | MyBiosource | 15nmol | 405 EUR |
TNFRSF10D siRNA (Human) |
|||
MBS8232418-30nmol | MyBiosource | 30nmol | 565 EUR |
TNFRSF10D siRNA (Human) |
|||
MBS8232418-5x30nmol | MyBiosource | 5x30nmol | 2450 EUR |
Human TNFRSF10D ELISA KIT |
|||
ELI-36682h | Lifescience Market | 96 Tests | 988.8 EUR |
Human TNFRSF10D shRNA Plasmid |
|||
20-abx955793 | Abbexa |
|
|
Human TNFRSF10D Protein Lysate |
|||
MBS8428897-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Recombinant Human TNFRSF10D Protein |
|||
E30P01243A | EnoGene | 50 ug | 295 EUR |
Anti-DcR2 TNFRSF10D Antibody |
|||
A05136-1 | BosterBio | 0.1mg | 449 EUR |
Description: Boster Bio Anti-DcR2 TNFRSF10D Antibody (Catalog # A05136-1). Tested in ELISA, WB, ICC, IHC-P, IF applications. This antibody reacts with Human, Mouse, Rat. |
|||
Human TNFRSF10D Protein, Fc Tag |
|||
E40KMPH6289 | EnoGene | 20ug | 495 EUR |
Human TNFRSF10D Protein, His Tag |
|||
E40KMPH1573 | EnoGene | 20ug | 495 EUR |
Human TNFRSF10D knockout cell line |
|||
ABC-KH15834 | AcceGen | 1 vial | Ask for price |
Description: Human TNFRSF10D knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
TNFRSF10D ORF Vector (Human) (pORF) |
|||
ORF010806 | ABM | 1.0 ug DNA | 114 EUR |
Human TNFRSF10D knockdown cell line |
|||
ABC-KD15834 | AcceGen | 1 vial | Ask for price |
Description: Human TNFRSF10D knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human TNFRSF10D Protein Lysate 20ug |
|||
IHUTNFRSF10DPLLY20UG | Innovative research | each | 213 EUR |
Description: Human TNFRSF10D Protein Lysate 20ug |
|||
Mouse Monoclonal anti-human TNFRSF10D EC |
|||
hAP-0579 | Angio Proteomie | 100ug | 250 EUR |
TNFRSF10D |
|||
CSB-CL887006HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
TNFRSF10D |
|||
cyt-1045 | ProSpec Tany | 1µg | 60 EUR |
Description: Recombinant Human TRAIL Receptor-4 |
|||
TNFRSF10D |
|||
MBS8564238-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 565 EUR |
TNFRSF10D |
|||
MBS8564238-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 565 EUR |
TNFRSF10D |
|||
MBS8564238-01mLAF610 | MyBiosource | 0.1mL(AF610) | 565 EUR |
TNFRSF10D |
|||
MBS8564238-01mLAF635 | MyBiosource | 0.1mL(AF635) | 565 EUR |
TNFRSF10D |
|||
MBS8564238-02mL | MyBiosource | 0.2mL | 345 EUR |
Mouse anti Human TRAIL R4/CD264/TNFRSF10D Monoclonal Antibody |
|||
MBS2543373-006mL | MyBiosource | 0.06mL | 250 EUR |
Mouse anti Human TRAIL R4/CD264/TNFRSF10D Monoclonal Antibody |
|||
MBS2543373-012mL | MyBiosource | 0.12mL | 370 EUR |
Mouse anti Human TRAIL R4/CD264/TNFRSF10D Monoclonal Antibody |
|||
MBS2543373-02mL | MyBiosource | 0.2mL | 550 EUR |
Recombinant Human TNFRSF10D, His tagged |
|||
TNFRSF10D-3169H | Creative BioMart | 100 µg | 454.4 EUR |
Description: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
|||
TNFRSF10D ELISA Kit (Human) (OKBB01434) |
|||
OKBB01434 | Aviva Systems Biology | 96 Wells | 606 EUR |
Description: Description of target: Decoy receptor 2 (DCR2), also known as TRAIL receptor 4 (TRAILR4) and tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), is a human cell surface receptor of the TNF-receptor superfamily. It is mapped to 8p21.3. The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplasmic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml |
|||
TNFRSF10D ELISA Kit (Human) (OKCA02319) |
|||
OKCA02319 | Aviva Systems Biology | 96 Wells | 913.2 EUR |
Description: Description of target: Receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis. Reports are contradictory with regards to its ability to induce the NF-kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway. ;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: 0.078 ng/mL |
|||
TNFRSF10D ELISA Kit (Human) (OKEH04990) |
|||
OKEH04990 | Aviva Systems Biology | 96 Wells | 715.2 EUR |
Description: Description of target: Receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis. Reports are contradictory with regards to its ability to induce the NF-kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway. ;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.078 ng/mL |
|||
Human TNFRSF10D Protein, Fc & His Tag |
|||
E40KMPH6272 | EnoGene | 20ug | 495 EUR |
Human TNFRSF10D Protein, Fc & His Tag |
|||
E40KMPH1572 | EnoGene | 20ug | 495 EUR |
TNFRSF10D antibody |
|||
38726 | SAB | 100ul | 439 EUR |
TNFRSF10D antibody |
|||
38726-100ul | SAB | 100ul | 302.4 EUR |
TNFRSF10D Antibody |
|||
35312 | SAB | 100ul | 319 EUR |
TNFRSF10D Antibody |
|||
35312-100ul | SAB | 100ul | 302.4 EUR |
TNFRSF10D Antibody |
|||
35312-50ul | SAB | 50ul | 224.4 EUR |
TNFRSF10D Antibody |
|||
ABD4811 | Lifescience Market | 100 ug | 525.6 EUR |
TNFRSF10D Antibody |
|||
CSB-PA031451- | Cusabio | each | 402 EUR |
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
TNFRSF10D Antibody |
|||
CSB-PA031451-100ul | Cusabio | 100ul | 379.2 EUR |
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA023967GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
|||
TNFRSF10D Antibody |
|||
DF4811 | Affbiotech | 200ul | 420 EUR |
TNFRSF10D Antibody |
|||
DF4811-100ul | Affinity Biosciences | 100ul | 168 EUR |
Description: WB,IF/ICC,ELISA(peptide) |
|||
TNFRSF10D Antibody |
|||
DF4811-200ul | Affinity Biosciences | 200ul | 210 EUR |
Description: WB,IF/ICC,ELISA(peptide) |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA057438 | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA070147 | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/10000 |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA08209A0Rb | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA909727 | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:100-1:300 |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA887006ESR1HU | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:200-1:1000, IHC:1:20-1:200 |
|||
TNFRSF10D Antibody |
|||
1-CSB-PA887006ESR2HU | Cusabio |
|
|
Description: A polyclonal antibody against TNFRSF10D. Recognizes TNFRSF10D from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
TNFRSF10D Antibody |
|||
E11-21301C | EnoGene | 100μg | 225 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Antibody |
|||
E035312 | EnoGene | 100μg/100μl | 255 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Antibody |
|||
E300301a | EnoGene | 100ug/200ul | 295 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Antibody |
|||
E312432 | EnoGene | 200ul | 275 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Antibody |
|||
E19-4811 | EnoGene | 100μg/100μl | 225 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Antibody |
|||
MBS2516914-006mL | MyBiosource | 0.06mL | 190 EUR |
TNFRSF10D Antibody |
|||
MBS2516914-012mL | MyBiosource | 0.12mL | 265 EUR |
TNFRSF10D Antibody |
|||
MBS2516914-02mL | MyBiosource | 0.2mL | 415 EUR |
TNFRSF10D Antibody |
|||
MBS2516914-5x02mL | MyBiosource | 5x0.2mL | 1835 EUR |
TNFRSF10D Antibody |
|||
MBS7131835-01mL | MyBiosource | 0.1mL | 270 EUR |
TNFRSF10D Antibody |
|||
MBS7131835-5x01mL | MyBiosource | 5x0.1mL | 1200 EUR |
TNFRSF10D Antibody |
|||
MBS7125425-005mL | MyBiosource | 0.05mL | 190 EUR |
TNFRSF10D Antibody |
|||
MBS7125425-01mL | MyBiosource | 0.1mL | 270 EUR |
TNFRSF10D Antibody |
|||
MBS7125425-5x01mL | MyBiosource | 5x0.1mL | 1205 EUR |
TNFRSF10D Antibody |
|||
MBS7125426-005mL | MyBiosource | 0.05mL | 190 EUR |
TNFRSF10D Antibody |
|||
MBS7125426-01mL | MyBiosource | 0.1mL | 270 EUR |
TNFRSF10D Antibody |
|||
MBS7125426-5x01mL | MyBiosource | 5x0.1mL | 1205 EUR |
TNFRSF10D Antibody |
|||
MBS7121152-005mg | MyBiosource | 0.05mg | 150 EUR |
TNFRSF10D Antibody |
|||
MBS7121152-01mg | MyBiosource | 0.1mg | 190 EUR |
TNFRSF10D Antibody |
|||
MBS7121152-5x01mg | MyBiosource | 5x0.1mg | 845 EUR |
TNFRSF10D Antibody |
|||
MBS8515514-01mg | MyBiosource | 0.1mg | 305 EUR |
TNFRSF10D Antibody |
|||
MBS8515514-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS8515514-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS8515514-01mLAF610 | MyBiosource | 0.1mL(AF610) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS8515514-01mLAF635 | MyBiosource | 0.1mL(AF635) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS9606265-01mL | MyBiosource | 0.1mL | 260 EUR |
TNFRSF10D Antibody |
|||
MBS9606265-02mL | MyBiosource | 0.2mL | 305 EUR |
TNFRSF10D Antibody |
|||
MBS9606265-5x02mL | MyBiosource | 5x0.2mL | 1220 EUR |
TNFRSF10D Antibody |
|||
MBS9510329-005mL | MyBiosource | 0.05mL | 285 EUR |
TNFRSF10D Antibody |
|||
MBS9510329-01mL | MyBiosource | 0.1mL | 385 EUR |
TNFRSF10D Antibody |
|||
MBS9510329-5x01mL | MyBiosource | 5x0.1mL | 1590 EUR |
TNFRSF10D Antibody |
|||
MBS856336-01mg | MyBiosource | 0.1mg | 305 EUR |
TNFRSF10D Antibody |
|||
MBS856336-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS856336-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS856336-01mLAF610 | MyBiosource | 0.1mL(AF610) | 465 EUR |
TNFRSF10D Antibody |
|||
MBS856336-01mLAF635 | MyBiosource | 0.1mL(AF635) | 465 EUR |
TNFRSF10D antibody |
|||
MBS9405762-005mL | MyBiosource | 0.05mL | 300 EUR |
TNFRSF10D antibody |
|||
MBS9405762-01mL | MyBiosource | 0.1mL | 390 EUR |
TNFRSF10D antibody |
|||
MBS9405762-5x01mL | MyBiosource | 5x0.1mL | 1610 EUR |
TNFRSF10D Antibody |
|||
MBS9507250-005mL | MyBiosource | 0.05mL | 285 EUR |
TNFRSF10D Antibody |
|||
MBS9507250-01mL | MyBiosource | 0.1mL | 385 EUR |
TNFRSF10D Antibody |
|||
MBS9507250-5x01mL | MyBiosource | 5x0.1mL | 1590 EUR |
TNFRSF10D Antibody |
|||
MBS9407376-005mL | MyBiosource | 0.05mL | 245 EUR |
TNFRSF10D Antibody |
|||
MBS9407376-01mL | MyBiosource | 0.1mL | 305 EUR |
TNFRSF10D Antibody |
|||
MBS9407376-5x01mL | MyBiosource | 5x0.1mL | 1230 EUR |
Anti-TRAIL-R4 TNFRSF10D Antibody |
|||
A05136 | BosterBio | 100ug | 607 EUR |
Description: Boster Bio Anti-TRAIL-R4 TNFRSF10D Antibody (Catalog# A05136). Tested in ICC, IHC, WB application(s). This antibody reacts with Human, Mouse, Rat. |
|||
DcR2 (TNFRSF10D) (NM_003840) Human Over-expression Lysate |
|||
E45H19123-2 | EnoGene | 20 ug | 395 EUR |
DcR2 (TNFRSF10D) (NM_003840) Human Over-expression Lysate |
|||
LS008793 | BosterBio | 100ug | 628 EUR |
Description: Transient overexpression lysate of tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain (TNFRSF10D) |
|||
Human DCR2/TNFRSF10D PicoKine ELISA Kit |
|||
MBS1752672-5x96StripWells | MyBiosource | 5x96-Strip-Wells | 2755 EUR |
Human DCR2/TNFRSF10D PicoKine ELISA Kit |
|||
MBS1752672-96StripWells | MyBiosource | 96-Strip-Wells | 600 EUR |
Recombinant Human TNFRSF10D, Fc-His tagged |
|||
TNFRSF10D-885H | Creative BioMart | 100 µg | 454.4 EUR |
Description: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
|||
Recombinant Human TNFRSF10D/TRAIL R4 Protein |
|||
RP00814 | Abclonal | 10μg | 85.02 EUR |
OKBB01434-96W - TNFRSF10D ELISA Kit (Human) |
|||
OKBB01434-96W | Aviva Systems Biology | 96wells | 538 EUR |
OKCA02319-96W - TNFRSF10D ELISA Kit (Human) |
|||
OKCA02319-96W | Aviva Systems Biology | 96Wells | 600 EUR |
OKEH04990-96W - TNFRSF10D ELISA Kit (Human) |
|||
OKEH04990-96W | Aviva Systems Biology | 96Wells | 475 EUR |
Human CellExp? TNFRSF10D / TRAIL R4, human recombinant |
|||
P1140-10 | Biovision | each | 157.2 EUR |
Human CellExp? TNFRSF10D / TRAIL R4, human recombinant |
|||
P1140-50 | Biovision | each | 470.4 EUR |
Human TRAIL R4 / TNFRSF10D Protein, His Tag |
|||
TR4-H52H5 | ACROBIOSYSTEMS | 1mg | 272.5 EUR |
Description: Human TRAIL R4, His Tag (TR4-H52H5) is expressed from human 293 cells (HEK293). It contains AA Ala 56 - His 211 (Accession # NP_003831). |
|||
TNFRSF10D sgRNA CRISPR Lentivector set (Human) |
|||
K2415801 | ABM | 3 x 1.0 ug | 406.8 EUR |
Human TRAIL R4/TNFRSF10D Recombinant Protein |
|||
PROTQ9UBN6 | BosterBio | 10ug | 265 EUR |
Description: Human TRAIL R4/TNFRSF10D Recombinant Protein expressed in Baculovirus with hIgG-His-tag. Sequence domain: 56-211aa. Application(s): SDS-PAGE, Bioactivity. Endotoxin: < 1 EU per 1ug of protein (determined by LAL method). |
|||
TNFRSF10D Antibody Pair |
|||
CSB-EAP08209-1pair596wellplates | Cusabio | 1 pair(5*96 well plates) | Ask for price |
Description: We recommend using the capture antibody at a concentration of 0.5ug/ml and the detection antibody at a concentration of 0.25ug/ml.Optimal dilutions should be determined experimentally by the researcher. |
|||
TNFRSF10D Antibody Pair |
|||
CSB-EAP08209-each | Cusabio | each | Ask for price |
Description: We recommend using the capture antibody at a concentration of 0.5ug/ml and the detection antibody at a concentration of 0.25ug/ml.Optimal dilutions should be determined experimentally by the researcher. |
|||
TNFRSF10D Antibody Pair |
|||
MBS7041926-1PairSufficientfor5x96wellplates | MyBiosource | 1Pair(Sufficientfor5x96wellplates) | 775 EUR |
TNFRSF10D Antibody Pair |
|||
MBS7041926-5x1PairSufficientfor25x96wellplates | MyBiosource | 5x1Pair(Sufficientfor25x96wellplates) | 3475 EUR |
Human DCR2/TNFRSF10D ELISA Kit PicoKine® |
|||
EK2067 | BosterBio | 96 wells | 499 EUR |
Description: Human DCR2/TNFRSF10D ELISA Kit PicoKine® (96 Tests). Quantitate Human TNFRSF10D in cell culture supernatants, serum and plasma (heparin, EDTA, citrate). Sensitivity: 10pg/ml. |
|||
TNFRSF10D Antibody (Center) |
|||
E45R06175G-1 | EnoGene | 100 ul | 395 EUR |
TNFRSF10D Antibody (Center) |
|||
E45R06175G-4 | EnoGene | 50 ul | 295 EUR |
TNFRSF10D Antibody (Center) |
|||
MBS9211624-008mL | MyBiosource | 0.08mL | 210 EUR |
TNFRSF10D Antibody (Center) |
|||
MBS9211624-04mL | MyBiosource | 0.4mL | 430 EUR |
TNFRSF10D Antibody (Center) |
|||
MBS9211624-5x04mL | MyBiosource | 5x0.4mL | 1910 EUR |
OOCA01712-25T - Human TNFRSF10D Primer Pair 1 |
|||
OOCA01712-25T | Aviva Systems Biology | 25Tests | 229 EUR |
OOCA01713-25T - Human TNFRSF10D Primer Pair 2 |
|||
OOCA01713-25T | Aviva Systems Biology | 25Tests | 229 EUR |
Human Decoy Receptor 2 (TNFRSF10D) ELISA Kit |
|||
IHUTNFRSF10DKT | Innovative research | each | 702 EUR |
Description: Human Decoy Receptor 2 (TNFRSF10D) ELISA Kit |
|||
Human Decoy Receptor 2 (TNFRSF10D) ELISA Kit |
|||
MBS8420084-1Kit | MyBiosource | 1Kit | 755 EUR |
Human Decoy Receptor 2 (TNFRSF10D) ELISA Kit |
|||
MBS8420084-5x1Kit | MyBiosource | 5x1Kit | 3455 EUR |
TNFRSF10D Protein Vector (Human) (pPM-C-HA) |
|||
PV043223 | ABM | 500 ng | 394.8 EUR |
TNFRSF10D Protein Vector (Human) (pPB-C-His) |
|||
PV043221 | ABM | 500 ng | 394.8 EUR |
TNFRSF10D Protein Vector (Human) (pPB-N-His) |
|||
PV043222 | ABM | 500 ng | 394.8 EUR |
TNFRSF10D Protein Vector (Human) (pPM-C-His) |
|||
PV043224 | ABM | 500 ng | 394.8 EUR |
TNFRSF10D Polyclonal Antibody |
|||
A54081 | EpiGentek |
|
|
TNFRSF10D Polyclonal Antibody |
|||
A71327 | EpiGentek |
|
|
TNFRSF10D Polyclonal Antibody |
|||
A71328 | EpiGentek |
|
|
TNFRSF10D polyclonal antibody |
|||
BS7929 | Bioworld Biotech | 50 ul | 358 EUR |
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-61175-120uL | Elabscience Biotech | 120uL | 320 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-61175-200uL | Elabscience Biotech | 200uL | 530 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-61175-60uL | Elabscience Biotech | 60uL | 200 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-61175-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-14934-120uL | Elabscience Biotech | 120uL | 240 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-14934-200uL | Elabscience Biotech | 200uL | 399 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-14934-20uL | Elabscience Biotech | 20uL | 73 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-14934-60uL | Elabscience Biotech | 60uL | 143 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-11141-120uL | Elabscience Biotech | 120uL | 240 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-11141-200uL | Elabscience Biotech | 200uL | 399 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-11141-20uL | Elabscience Biotech | 20uL | 73 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-11141-60uL | Elabscience Biotech | 60uL | 143 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-17834-120uL | Elabscience Biotech | 120uL | 240 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-17834-200uL | Elabscience Biotech | 200uL | 399 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-17834-20uL | Elabscience Biotech | 20uL | 73 EUR |
Description: Unconjugated |
|||
TNFRSF10D Polyclonal Antibody |
|||
E-AB-17834-60uL | Elabscience Biotech | 60uL | 143 EUR |
Description: Unconjugated |
|||
TNFRSF10D Conjugated Antibody |
|||
C35312 | SAB | 100ul | 476.4 EUR |
TNFRSF10D Polyclonal Antibody |
|||
E914078 | EnoGene | 100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Polyclonal Antibody |
|||
E96136 | EnoGene | 100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
TNFRSF10D Polyclonal Antibody |
|||
MBS2517702-002mL | MyBiosource | 0.02mL | 135 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2517702-006mL | MyBiosource | 0.06mL | 190 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2517702-012mL | MyBiosource | 0.12mL | 265 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2517702-02mL | MyBiosource | 0.2mL | 415 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2517702-5x02mL | MyBiosource | 5x0.2mL | 1835 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2561627-002mL | MyBiosource | 0.02mL | 140 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2561627-006mL | MyBiosource | 0.06mL | 180 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2561627-012mL | MyBiosource | 0.12mL | 260 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2561627-02mL | MyBiosource | 0.2mL | 405 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2561627-5x02mL | MyBiosource | 5x0.2mL | 1725 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2559723-002mL | MyBiosource | 0.02mL | 135 EUR |
TNFRSF10D Polyclonal Antibody |
|||
MBS2559723-006mL | MyBiosource | 0.06mL | 190 EUR |
The marine polysaccharide-based DDS combines the benefits of polysaccharide supplies and nanotechnology, and is appropriate as a provider for completely different pharmaceutical preparations. This assessment summarizes the benefits and drawbacks of utilizing marine polysaccharides to assemble the NDDS and describes the preparation strategies and modification methods of marine polysaccharide-based nanocarriers.
0